Significant improvement of atrophy after eradication therapy in atrophic body gastritis

被引:31
作者
Oberhuber, G
Wuendisch, T
Rappel, S
Stolte, M
机构
[1] Klinikum Bayreuth, Inst Pathol, D-95410 Bayreuth, Germany
[2] Univ Vienna, Inst Clin Pathol, AKH, Vienna, Austria
关键词
H-pylori; atrophic body gastritis; eradication therapy;
D O I
10.1016/S0344-0338(98)80095-2
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Chronic atrophic body gastritis may be induced by H. pylori. Results on the effect of H. pylori eradication therapy have been conflicting. Here, we report on the effect of eradication therapy on both body atrophy and inflammation in 7 patients. They presented with severe or moderate atrophy of the oxyntic mucosa and positive H. pylori histology (Warthin-Starry) and/or serology. Eradication was performed with a standard double or triple therapy regimen. At least 6 weeks after successful eradication therapy, patients underwent rebiopsy and histopathological evaluation of the gastric body. In all 7 patients, the grade of body gastritis improved significantly. Among the patients with severe atrophy before H. pylori eradication, 2 had normal mucosa, 3 low-grade atrophy, and one moderate atrophy after treatment. The one case with moderate atrophy before treatment had normal mucosa after H. pylori eradication. In addition, inflammatory infiltration of the mucosa cleared up in 6 cases and improved from severe to mild in one case after treatment. From these results, we conclude that in patients with histologically demonstrated H. pylori and/or positive H. pylori serology atrophic body mucosa can recover after successful eradication therapy.
引用
收藏
页码:609 / 613
页数:5
相关论文
共 31 条
  • [1] Atrophic body gastritis: Distinct features associated with Helicobacter pylori infection
    Annibale, B
    Marignani, M
    Azzoni, C
    DAmbra, G
    Caruana, P
    DAdda, T
    DelleFave, G
    Bordi, C
    [J]. HELICOBACTER, 1997, 2 (02) : 57 - 64
  • [2] [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1
  • [3] Molecular mimicry between Helicobacter pylori and the host
    Appelmelk, BJ
    Negrini, R
    Moran, AP
    Kuipers, EJ
    [J]. TRENDS IN MICROBIOLOGY, 1997, 5 (02) : 70 - 73
  • [4] DOUBLE-BLIND TRIAL OF OMEPRAZOLE AND AMOXICILLIN TO CURE HELICOBACTER-PYLORI INFECTION IN PATIENTS WITH DUODENAL-ULCERS
    BAYERDORFFER, E
    MIEHLKE, S
    MANNES, GA
    SOMMER, A
    HOCHTER, W
    WEINGART, J
    HELDWEIN, W
    KLANN, H
    SIMON, T
    SCHMITT, W
    BASTLEIN, E
    EIMILLER, A
    HATZ, R
    LEHN, N
    DIRSCHEDL, P
    STOLTE, M
    [J]. GASTROENTEROLOGY, 1995, 108 (05) : 1412 - 1417
  • [5] Italian omeprazole triple therapy - A 1-week regimen
    Bazzoli, F
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1996, 31 : 118 - 118
  • [6] LONG-TERM SEQUELAE OF HELICOBACTER-PYLORI GASTRITIS
    BEALES, ILP
    DAVEY, NJ
    PUSEY, CD
    LECHLER, RI
    CALAM, J
    [J]. LANCET, 1995, 346 (8971): : 381 - 382
  • [7] Carneiro F, 1993, Eur J Cancer Prev, V2, P239, DOI 10.1097/00008469-199305000-00008
  • [8] CORREA P, 1992, CANCER RES, V52, P6735
  • [9] Classification and grading of gastritis - The updated Sydney System
    Dixon, MF
    Genta, RM
    Yardley, JH
    Correa, P
    Batts, KP
    Dahms, BB
    Filipe, MI
    Haggitt, RC
    Haot, J
    Hui, PK
    Lechago, J
    Lewin, K
    Offerhaus, JA
    Price, AB
    Riddell, RH
    Sipponen, P
    Solcia, E
    Watanabe, H
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (10) : 1161 - 1181
  • [10] Helicobacter pylori infection and chronic gastric acid hyposecretion
    ElOmar, EM
    Oien, K
    ElNujumi, A
    Gillen, D
    Wirz, A
    Dahill, S
    Williams, C
    Ardill, JES
    McColl, KEL
    [J]. GASTROENTEROLOGY, 1997, 113 (01) : 15 - 24